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Steroid-resistant nephrotic syndrome (SRNS) in children carries a signiﬁcant risk of progression to end-stage renal failure (ESRF).
We report a two-step protocol adapted in children with SRNS. Thirty-seven SRNS were treated with cyclosporine A (CyA) in
association with prednisolone (alternate day) for 6 months (ﬁrst-step treatment). Twelve patients (32.4%) went into complete
remission, and 2 (5.4%) got partial remission. The other 23 cases who were steroid and CyA resistant entered a second-step
treatment with withdrawing steroids, with CyA (5mg/kg/day) in association with mycophenolate mofetil (MMF) 30mg/kg/day
for 6 months. Complete remission was observed in 11 cases (47.82%) and partial remission in 2 cases (8.7%). After two steps of
treatment, 27/37 children went into total remission. In steroid and CyA-resistant INS, the association of MMF with CyA was able
to induce remission in about half cases without relevant side eﬀects.
1.Introduction
Idiopathic nephrotic syndrome (INS) includes minimal
change disease (MCD), focal segmental glomerulosclerosis
(FSGS), and diﬀuse mesangial proliferation (DMP). Patients
withMCDusuallyhaveexcellentprognosis,butpatientswith
FSGS and DMP often have hypertension, hematuria, and
progress to renal failure [1–4]. Steroid dependence or resis-
tance seems to have increased over the last decades, but the
treatmentofdiﬃcultcasesofINS,mostlyduetoFSGS,isstill
a challenge [5–7]. A number of medications such as (MP)
[7], cyclophosphamide [8], vincristine [9], MMF, and Cy A
[10, 11] have been used with varying result. Recent reports
have showed remission rates ranging from 20% to 70%
using these drugs in SRINS [10, 11]. But serious side eﬀects
of these medications such as nephrotoxicity, hypertension,
hirsutism, arrhythmias, psychosis, growth retardation, and
severe infections remain a major problem [7–10]. Hence, the
search for a rescue therapy in diﬃcult cases of INS is needed
in order to avoid unnecessary exposure to toxic drugs. An
optimal combination of immunosuppresive agents to reverse
resistance and to reduce the undesirable eﬀects of high dose
and prolonged administration of drugs is still a challenge
(11, 4). Moreover, there are some reports supporting the idea
that MCD, DMP, and FSGS are separate diseases because of
diﬀerent response rate to corticosteroid and the histologic
ﬁndings oﬀer data of prognostic signiﬁcance [12]. Therefore,
in many centers, renal biopsy is recommended according to
the rationale that the intensity of immunosuppression may
have to be adapted to the underlying ﬁndings in renal biopsy
for the patients who do not respond to steroids [11–13].
In this study, patients with SRNS were treated in a ﬁrst
step protocol with a combination of Cy A (5mg/kg/day)
in association with prednisolone (1mg/kg on alternate
day) for 6 months. In resistant cases, prednisolone was
withdrawnandCyA(5mg/kg/day)inassociationwithMMF
(30mg/kg/day) was adapted as second step for 6 months.
2.Methods andMaterials
Patients admitted to our hospital between October 2002 and
April 2008 fulﬁlling the entering criteria of INS (proteinuria2 International Journal of Nephrology
>50mg/kg/24hr, serum albumin <3g/dl, total cholesterol
>250g/dl, and edema) were included in this study. Children
were treated with prednisolone 2mg/kg/day for 4 weeks in
case of remission, for 6 weeks in case of no remission.
The following criteria were adopted for assessing the
patient’s response to medication:
(i) complete remission: serum albumin ≥2.5g% and
absence of proteinuria or proteinuria <4mg/kg/day ,
(ii) partial remission: serum albumin ≥2.5g% and 50%
reduction of initial proteinuria (<50mg/kg/day),
(iii) no response: persistence of hypoalbuminemia (<2.5
g%) and nephrotic proteinuria (≥50mg/kg/day).
Patients with INS, older than 1 year and younger than
14 years old, without hypertension, macroscopic haematuria
which went into remission with prednisolone (2mg/kg/day)
by 6 weeks, considered as SSNS and did not undergo kidney
biopsy.
Patients who did not reach remission after 6 weeks of
prednisolone (SSNS) underwent kidney biopsy which was
examined by light microscope alone, since immunoﬂuores-
cence and electron microscope were not available.
First-step protocol for SRNS was the following: Cy A
(5mg/kg/24hr) and prednisolone (1mg/kg/day) every other
day for 6 months. If remission was obtained 3 month after
complete remission, prednisolone was discontinued.
Second-step protocol for patients who did not go into
remission on the ﬁrst step: treatment Cy A 5mg/kg/day and
MMF 30mg/kg/day were given for 6 months with with-
drawing Prednisolone. If complete remission was obtained,
3 month later CyA was tapered. With any relapse during
tapering phase, we go back again to previous dose of
cyclosporine.
Patients were monitored every 2 weeks for ﬁrst 2 months,
monthly for the next 6 months and every 2 months
thereafter.
Data analyzed by chi square test with using two methods;
Likelihood Ratio Test and Fisher’s exact test. The P value
was estimated Mont Carlo and exact distribution and value
<0.05 was considered signiﬁcant. In this study we used SPSS
software version 16.
3. Results
One hundred patients with INS were investigated. A few
cases were lost from followup (3 cases), 2 had congenital
nephroticsyndrome,onehadnephroticsyndromeassociated
with systemic lupus erythematosus, and 4 with membra-
noproliferative glomerulonephritis were not included in the
study protocol. The remaining 90 patients considered suﬀer
from INS entered the protocol.
Thirty-one children(34.4%) werefemaleand59(65.6%)
male (male to female ratio 1.9:1).
In this study, 53 children (58.9%) responded well to
steroid therapy, and thus did not undergo renal biopsy.
Thirty-seven cases (41.1%) were resistant to steroid therapy
and underwent renal biopsy and included DMP 11 cases
(12.2%),FSGS10cases(11.1%),andMCD16cases(17.8%).
Table 1: Demography of 37 corticosteroid resistant nephritic
syndrome.
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In this group 15 (40.5%) children were <4 years old (y.o), 12
(32.5%) were between 4–10 (y.o), and 10 (27%) were >10
(y.o). The most common age group was <4 years, and the
mean age of the patients was 7.2 ±3.76 years (Table 1).
Of 37 SRNS, 12 cases (32.4%) completely responded to
ﬁrst-step protocol and 2 cases (5.4%) partially responded
to this regimen (Table 2). Steroid therapy was tapered
in 12 children with complete remission and eventually
discontinued in 8 children (7 MCD and 1 DMP) 3 months
after complete remission.
Other 23 children remained steroid and CyA resis-
tant and entered the second-step treatment. Eleven cases
(47.82%) completely responded to CyA in association
with MMF (second step), and 2 cases (8.7%) partially
responded to this regimen (Table 2). We slowly tapered
CyA (1mg/kg/month) in 11 cases 3 months after the
complete remission. All cases maintained remission with
CyA (3mg/kg) in association with MMF (30mg/kg/day).
WhenCyAwasdecreasedto2mg/kg,7/11cases(6caseswith
DMP and 1 cases with FSGS) completely and 2/11(MCD)
partially relapsed.
The highest rate of response to steroid was in the age
croup of 4–10 years (49%) and the highest rate of steroid
resistance was in the smaller children <4 years old (41%).
Signiﬁcant diﬀerence in complete response to combi-
nation therapy was found among the three groups (MCD,
FSGS, and DMP) (Tables 3 and 4). The highest response rate
toCyAandprednisolonewasobservedinpatientswithMCD
(37.8%). The highest response rate to MMF and CyA was
seen in DMP cases (56.5%). Ten cases were resistant to all
drug categories.
Side eﬀects of treatment were striae in 11, hypertrichosis
in 9 and gingival hyperplasia in 5, and cataract in 3 patients
in the end of ﬁrst-step protocol. In the second-step protocol
side eﬀects of treatment were diarrhea in 3, abdominal pain
in 4, and mild anemia in 3 patients.International Journal of Nephrology 3
Table 3: Frequency of response to prednisolone + cyclosporine A





MCD 6 (37.5%) 10 (62.5%) 16 (100%)
DMP 8 (72.4%) 3 (27.3%) 11 (100%)
FSGS 9 (90%) 1 (10%) 10 (100%)
(b)
Statistical test Monte Carlo∗ Exact sig






Fishers Exact test Sig = 0.023∗ P = 0.023
∗Based on 1000 sampled tables.







MCD 2 (33.3%) 4 (66.7%) 6 (100%)
DMP 1 (12.5%) 7 (87.5%) 8 (100%)
FSGS 7 (77.8%) 2 (22.2%) 9 (100%)
(b)
Statistical test Mont Carlo Exact sig






Fishers exact test Sig = 0.021∗ P = 0.021
∗Based on 1000 sampled tables.
4. Discussion
Children with SRNS have been treated with various medi-
cation, including CyA, MMF, cyclophosphamide, and aza-
thioprine. In recent studies, the rate of complete remission
after using diﬀerent immunosuppressive agents varies from
30% to 84%, depending on the treatment protocols [11,
14, 15] .I nas t u d yb yJ a m e e l aA .K a r i ,t w e n t yo fc h i l d r e n
with SRNS (65%) achieved partial (6) and complete (14)
remission. In this report, 16 children was treated with
cyclophosphamide either oral or intravenous, and only 4 of
them (25%) achieved remission. Seven children received oral
chlorambucil, and only 2 of them (28.5%) got remission.
Fifteen children received CyA, and 8 of them (53%) achieved
remission.MMFwasusedin5children,and2(40%)ofthem
attained complete remission [15]. However because of unfa-
vorable side eﬀects, variable eﬃcacy and high relapse rate in
the literature, the alkylating agents are not recommended for
primary therapy in SRNS [4, 6, 15]. In another report with
usingCyAinassociationwithprednisoloneinSRNSfortime,
75% of cases got remission [11].
In our study the total remission was 73/1% (sum of
remission obtained within ﬁrst and the second protocol
steps). Diﬀerence in complete response to combination
therapy between three groups (MCD, FSGS, and DMP) was
statically signiﬁcant (Tables 3 and 4). The highest response
rate to cyclosporine A + prednisolone was seen in patients
with MCD (37.8%), but the highest response rate to MMF +
cyclosporine A was detected in DMP cases (56.5%) (Tables
3 and 4). Seven cases which were resistant to all drugs had
FSGS in biopsy and Only 3 cases (30%) with FSGS got
remission (by ﬁrst and second step) see Tables 3 and 4.
It is possible that the response rates in SRNS to immuno-
suppressants may vary according to the type of glomerular
lesion and unknown multiple factors. Comparison between
FSGS data and MCD data by Ehrich et al. has supported
the concept that the type of underlying glomerular lesion
in idiopathic SRNS may inﬂuence the response to treatment
[11].
In the present study, the highest remission rate to steroid
therapy was observed in the age of 4–10 years, and the
highestresistanceratetosteroidwasseeninchildren<4years
old (Table 2). Other studies indicate increasing frequency in
SRNS especially in young children [2, 11].
Regarding irreversible side eﬀects of long-term use of
steroid especially in young children (growth retardation,
cataract, and striae), it is suggested to use other medication
such as MMF. The use of MMF in glomerulonephritis is
based in its anti-inﬂammatory, antiﬁbrotic, antiproteinuric,
and inhibitory eﬀects to mesangial cell proliferation [16].
Recently, Li et al. have reported that MMF is tolerated and
signiﬁcantly decrease urinary protein excretion in children
less than 2 years old with SRNS [17]. In a randomized
controlled multicenter study the eﬃcacy of MMF versus CyA
in children with relapsing MCD was investigated. In this
study, MMF was given at maximum dose of 2gr/day and
CyA at dose of 4-5mg/kg/day (for 12 months). Although the
relapsed rate of nephrotic syndrome was higher in the MMF
group, but the renal function was better preserved and the
side eﬀects were less observed with MMF [18]. In order to
avoid high doses and long-term use of corticosteroid, some
studies recommend the association of CyA or MMF with low
dose corticostroide. MMF seems to be eﬀective at least in
some steroid and CyA resistant INS, but there are not reports
aboutusingof combination of MMFwithCyA in steroidand
CyA resistant INS.
ConsideringfavorableexperienceswithMMFsuchasless
adverse eﬀects than other immunosuppressive drugs, beneﬁt
eﬀects in the treatment of many immunologically mediated
renal diseases, and the antiﬁbrotic and antiproliferative
eﬀects of this medication [17, 18], it is suggested that MMF
in association with low-dose CyA (after remission) can be
a promising treatment of diﬃcult cases of steroid and CyA
resistant INS.
In our series of cases, FSGS was the most common type
of renal lesion in cases resistant to all therapy regimens.
Only 3/10 cases (30%) with steroid resistant FSGS achieved
remission the using ﬁrst treatment (1 case) and the second
step (2 cases).4 International Journal of Nephrology
In some of these cases, we cannot exclude genetic
mutations in podocyte-speciﬁc genes wich may inﬂuence
the response to treatment [19–21]. Other important ﬂaw
of our study is loss of immunoﬂuorescence and electron
microscopic ﬁnding in kidney biopsy which was examined
by light microscope alone, since immunoﬂuorescence and
electron microscope were not available.
Sensitivity rate of INS to steroid therapy was 58.9% in
our study and 70%–80% in other reports [22–24]. It could
be because of treating sensitive cases in provinces and not to
referring them to our center.
Patients were monitored every 2 weeks for ﬁrst 2 months,
monthly for the next 4 months, and every 3 months
thereafter.Therewasnosigniﬁcantsideeﬀect,andnochange
in dose of medication was made.
In conclusion, MMF in associated with CyA-induced
remission in signiﬁcant number of steroid and cyclosporine-
resistant NS and kept them in remission with low-dose CyA.
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